US 12,152,038 B2
Vasopressin receptor antagonists and products and methods related thereto
Robert M. Jones, San Mateo, CA (US); Mariangela Urbano, Del Mar, CA (US); Gary Brandt, Alameda, CA (US); Mark Chambers, Saffron Walden (GB); David Hardick, Saffron Walden (GB); Chris Knight, Saffron Walden (GB); Jason Tierney, Saffron Walden (GB); and Chris Lock, Saffron Walden (GB)
Assigned to Neumora Therapeutics, Inc., Watertown, MA (US)
Filed by Neumora Therapeutics, Inc., Watertown, MA (US)
Filed on Mar. 5, 2021, as Appl. No. 17/194,069.
Application 17/194,069 is a continuation of application No. 16/944,006, filed on Jul. 30, 2020, abandoned.
Application 16/944,006 is a continuation of application No. 16/703,714, filed on Dec. 4, 2019, abandoned.
Application 16/703,714 is a continuation of application No. 16/122,780, filed on Sep. 5, 2018, granted, now 10,538,530, issued on Jan. 21, 2020.
Claims priority of provisional application 62/554,452, filed on Sep. 5, 2017.
Prior Publication US 2021/0317126 A1, Oct. 14, 2021
Int. Cl. C07D 487/10 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/10 (2013.01) [A61P 9/00 (2018.01); A61P 25/00 (2018.01); A61P 25/18 (2018.01); A61P 25/20 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); C07D 519/00 (2013.01); C07B 2200/07 (2013.01)] 123 Claims
 
1. A method for treating a neuropsychological disorder, comprising administering to a subject afflicted with a neuropsychological disorder an effective amount of a compound having the structure of Formula (I) or a pharmaceutically acceptable stereoisomer, racemate, isotope, or salt thereof:

OG Complex Work Unit Chemistry
wherein:
X is —(CRxRy)nO(CRxRy)q—, —(CRxRy)nS(O)t(CRxRy)q—, —(CRxRy)nN(Rx)(CRxRy)q—, or —(CRxRy)n—,
Rx is, at each occurrence, independently H, lower alkyl, lower haloalkyl, halo, or R6;
Ry is, at each occurrence, independently H, —OH, lower alkyl, lower alkoxy, or halo;
Q1 is N or CR1a, Q2 is N or CR1b, and Q3 is N or CR1c, wherein at least one Q1, Q2, or Q3 is not N;
R1a, R1b, and R1c are each, independently, H, lower alkyl, lower haloalkyl, lower alkoxy, cyano, or halo;
R2a and R2b are each, independently, H, lower alkyl, lower haloalkyl, or lower alkoxy;
R3 is —(CHRz)m-Q-(R4)p, —S(═O)2R5, or —C(═O)R5;
Rz is H or CH3
Q is aryl or heteroaryl;
R4 is, at each occurrence, independently H, —OH, ═O, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, halo, or cyano;
R5 is H, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, aryl, heteroaryl, cycloalkylalkyl, heterocyclyl, or —O-heterocyclyl;
R6 is cycloalkyl, heterocyclyl, or —C(═O)R7;
R7 is H, lower alkyl, or lower haloalkyl;
n is 0, 1, or 2;
q is 0, 1, or 2;
t is 0, 1, or 2;
m is 0, 1, 2, 3, 4, 5, or 6; and
p is 0, 1, or 2.